» Articles » PMID: 28631728

ACG and CAG Clinical Guideline: Management of Dyspepsia

Overview
Specialty Gastroenterology
Date 2017 Jun 21
PMID 28631728
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dyspepsia are investigated with upper gastrointestinal endoscopy to exclude organic pathology. This is a conditional recommendation and patients at higher risk of malignancy (such as spending their childhood in a high risk gastric cancer country or having a positive family history) could be offered an endoscopy at a younger age. Alarm features should not automatically precipitate endoscopy in younger patients but this should be considered on a case-by-case basis. We recommend patients <60 years of age have a non-invasive test Helicobacter pylori and treatment if positive. Those that are negative or do not respond to this approach should be given a trial of proton pump inhibitor (PPI) therapy. If these are ineffective tricyclic antidepressants (TCA) or prokinetic therapies can be tried. Patients that have an endoscopy where no pathology is found are defined as having functional dyspepsia (FD). H. pylori eradication should be offered in these patients if they are infected. We recommend PPI, TCA and prokinetic therapy (in that order) in those that fail therapy or are H. pylori negative. We do not recommend routine upper gastrointestinal (GI) motility testing but it may be useful in selected patients.

Citing Articles

Unveiling the therapeutic effects of traditional Chinese patent medicines: A network meta-analysis on chronic atrophic gastritis.

Ren B, Zhong M, Yu C, Xiong M, Zhou S, Gao Q Medicine (Baltimore). 2025; 104(10):e41690.

PMID: 40068066 PMC: 11902981. DOI: 10.1097/MD.0000000000041690.


Itopride in functional dyspepsia: open-label, 1-year treatment follow-up of two multicenter, randomized, double-blind, placebo-controlled trials.

Broeders B, Tack J, Talley N Therap Adv Gastroenterol. 2025; 18:17562848251321123.

PMID: 39989849 PMC: 11843690. DOI: 10.1177/17562848251321123.


Functional dyspepsia and gastroparesis: are they distinct disorders, a spectrum of diseases or one disease?.

Egboh S, Duncanson K, Potter M, Keely S, Talley N eGastroenterology. 2025; 3(1):e100119.

PMID: 39944931 PMC: 11770444. DOI: 10.1136/egastro-2024-100119.


A Non-Pharmacological Paradigm Captures the Complexity in the Mechanism of Action of Poliprotect Against Gastroesophageal Reflux Disease and Dyspepsia.

Caterbi S, Buttarini C, Garetto S, Franco Moscardini I, Ughetto S, Guerrini A Int J Mol Sci. 2025; 26(3).

PMID: 39940951 PMC: 11818618. DOI: 10.3390/ijms26031181.


Approach to Meal-Related Nausea and Vomiting.

Cangemi D, Chase R, Lacy B Gastroenterol Hepatol (N Y). 2025; 21(1):19-27.

PMID: 39897340 PMC: 11784569.


References
1.
Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

2.
Lewin van den Broek N, Numans M, Buskens E, Verheij T, de Wit N, Smout A . A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract. 2001; 51(469):619-24. PMC: 1314070. View

3.
Bekhti A, Rutgeerts L . Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J. 1979; 55 Suppl 1:30-2. View

4.
Stake-Nilsson K, Soderlund M, Hultcrantz R, Unge P . A qualitative study of complementary and alternative medicine use in persons with uninvestigated dyspepsia. Gastroenterol Nurs. 2009; 32(2):107-14. DOI: 10.1097/SGA.0b013e31819e4be7. View

5.
Van de Mierop L, Rutgeerts L, Van den Langenbergh B, STAESSEN A . Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation. Digestion. 1979; 19(4):244-50. DOI: 10.1159/000198352. View